Longitudinal Assessment of an 800 µg Dose of HEBERSaVax in Non-Human Primates over Six Months

Background/Objectives: HEBERSaVax is a therapeutic cancer vaccine based on recombinant human VEGF antigen adjuvated with VSSP or Aluminum Phosphate (AP). Clinical trials demonstrated the vaccine’s safety and tolerability, with predominantly mild to moderate (grade 1–2) local adverse events. Initial...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Camila Canaán-Haden, Isabel Gonzalez-Moya, Monica Bequet-Romero, Olivia Cabanillas-Bernal, Rafael Martínez-Castillo, Camilo Cerioli-Pentón, Nayelis Chavez-Castro, Marta Ayala-Ávila, Jorge Castro-Velazco, Alexei F. Licea-Navarro, Yanelys Morera-Díaz
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2026-02-01
coleção:	Vaccines
Assuntos:	HEBERSaVax VEGF vaccine immunogenicity safety
Acesso em linha:	https://www.mdpi.com/2076-393X/14/3/230
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!